The release of the Australian federal government’s ‘ Science, Research and Innovation Budget Tables’ this week reveals the losses of almost A$400 million ($374 million) to science, research and innovation, prompting trade group AusBiotech to reinforce its calls for urgent and specific action that will drive growth in the biotechnology industry and therefore the Australian economy.
AusBiotech is urging federal government action to capitalize on the opportunity that Australian biotechnology represents, acknowledging the critical role public policy plays in the development of the industry and in turn industry’s ability to deliver to the economy with jobs of the future, as well as the new technologies that enhance and extend lives.
By incentivising desirable behaviors to build Australia’s innovation ecosystem in a global context, such as providing globally competitive tax policy, and in providing support where the ecosystem currently has gaping holes, the government can make a pivotal difference to the economic prospects.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze